Intravenous immunoglobulin (IVIG) is a blood/plasma product, which is prepared from the serum of multiple of donors, used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. IVIG is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology.
The Malaysia IVIG market was valued at $12,277 thousand in 2015, and is projected to reach $18,649 thousand by 2022, registering a CAGR of 6.1% during the forecast period. This is attributed to increase in prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) & hypogammaglobulinemia and rise in use of immunoglobulins to treat Guillain-Barre syndrome (GBS), inflammatory myopathies, specific antibody deficiency, and others. Increase in geriatric population & number of hemophilic patients, improved IVIG production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) drive the growth of the market. However, stringent government regulations toward IVIG products, expensive therapy, and high risk of side effects associated with the use of IVIG are expected to hamper the market growth.
The report segments the Malaysia IVIG market based on application, product type, mode of delivery, and concentration by both- value and volume. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, Kawasaki disease, secondary immune deficiency disease, and others.
Hypogammaglobulinemia and CIDP held dominant market shares in 2015 due to the large patient population and unavailability of effective alternatives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous, subcutaneous, and intramuscular. On the basis of concentration, it is categorized into 5%, 10%, and others. The intravenous mode of delivery segment held the largest revenue share in 2015, and is anticipated to continue this trend during the forecast period.
KEY PLAYERS PROFILED
Grifols S.A.,
Octapharma AG
Green Cross Corporation
Baxalta (Shire)
Bio Products Laboratory Ltd.
Biotest AG,
CSL Behring
Omrix Biopharmaceuticals Ltd.
Bayer Healthcare
Baxter International Inc.
KEY MARKET BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the Malaysia IVIG market and the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2014 to 2022 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market based on applications assists to understand the trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunodeficiency Diseases
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain-Barre Syndrome
Kawasaki Disease
Secondary Immune Deficiency
Others
By Product
IgG
IgA
IgM
IgE
IgD
By Mode of Delivery
Intravenous
Intramuscular
Subcutaneous
By Concentration
5% Concentration
10% Concentration
Other Concentration
The other players in the value chain include (profiles not included in the report)
BDI Pharma, Inc.
China Biologics Products, Inc.
LFB Biotechnologies
Hualan Biological Engineering Inc.
Guizhou Taibang Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd.
Shanghai Raas Blood Products Co. Ltd.
